Proactive Investors - Run By Investors For Investors

Imugene’s shares surge higher following early promise in gastric cancer trial

The company is well funded with a cash balance of circa $12 million as at 31 December 2017.
Imugene’s shares surge higher following early promise in gastric cancer trial
The vaccine induced strong immune responses in patients with metastatic gastric cancer

Imugene Limited’s (ASX:IMU) shares are trading circa 21% higher intra-day at $0.017 following early promise in gastric cancer clinical trial for its HER-Vaxx cancer vaccine (IMU-131).

HER-Vaxx is a next generation HER2 cancer therapy using B cell peptides, which harness the body’s ability to develop antibodies against the disease.

Imugene’s latest clinical results indicate that IMU-131 induces strong immune responses in patients with metastatic gastric cancer, with antibodies to the target cancer biomarker strongly evident in validated assays.

Importantly, clinicians have reported no safety, toxicity or tolerability issues with HER-Vaxx during the first cohort dosing of patients.

Dose escalation recommended

The cohort review committee for the study has reviewed the results and has recommended dose escalation.

The clinicians at eight sites across Hong Kong, Taiwan and Thailand will determine if the administration of HER-Vaxx in combination with chemotherapy will prolong survival, delay tumour progression, or reduce the tumour burden in patients with metastatic gastric cancer.

Multi-billion dollar market

HER-Vaxx works by targeting the same receptor as Herceptin and Perjeta, two leading antibody drugs marketed by Roche, with annual sales of US$8.2 billion.

Unlike Herceptin and Perjeta, which are “injected synthetic antibody” products, HER-Vaxx activates the patient’s own immune system to produce a continuous supply of cancer targeting antibodies and induce a response against the tumours.

The early clinical data for HER-Vaxx is encouraging, indicating immune activation in vaccinated patients in a manner that is consistent with the vaccine’s postulated mechanism of action.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

Medical scanner
February 09 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
picture of a knee
May 21 2019
We take a closer look at Collagen Solutions, which received third-party validation of its business model in the form of outside investment from a blue-chip US agriculture company
scientist in lab
February 26 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use